AI summary · may contain errors
Faricimab treat-and-extend in diabetic macular edema maintained visual and anatomic gains over RHONE-X, with adjusted BCVA improvements up to +11.4 letters and CST reductions near -205 µm.
- Open access
- 1 cites
Moving in Ophthalmology, Investigative Ophthalmology & Visual Science, Experimental Eye Research, bioRxiv, Diabetes, Journal of Extracellular Vesicles, Molecular Therapy and Progress in Retinal and Eye Research.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Faricimab treat-and-extend in diabetic macular edema maintained visual and anatomic gains over RHONE-X, with adjusted BCVA improvements up to +11.4 letters and CST reductions near -205 µm.
AI summary · may contain errors
Prophylactic fingolimod (0.3 mg/kg/day) given for 21 days in male Wistar albino rats significantly reduced proliferative vitreoretinopathy severity after intravitreal autologous PRP injection.
AI summary · may contain errors
Intravitreal autologous regulatory T cell-derived exosomes plus ranibizumab in refractory neovascular age-related macular degeneration shows a dose ceiling at 0.05 mg, with 0.5 mg linked to dose-limiting toxicity.
AI summary · may contain errors
In a 10-year type 2 diabetes cohort, 27% of eyes worsened and 21% improved, and OCTA-identified microvascular nonperfusion distinguished worsening/stable eyes from improving eyes.
AI summary · may contain errors
In JR5558 mice with neovascular age-related macular degeneration, P4HA1-driven proline hydroxylation is linked to subretinal fibrovascular lesion progression, with 4-hydroxyproline elevated by 4 weeks.
AI summary · may contain errors
Pharmacological inhibition of valosin-containing protein with ML240 significantly preserves cone photoreceptors in the cpfl1 mouse model of achromatopsia, improving cone density and opsin trafficking.
AI summary · may contain errors
Cambridge prophylactic cryotherapy is apparently safe and is linked to a 5.7-fold lower risk of retinal detachment in a national cohort of genetically confirmed type 2 Stickler syndrome patients.
AI summary · may contain errors
Anti-VEGF therapy is best supported for Zone I, posterior Zone II, and aggressive ROP, enabling rapid regression while raising risks like persistent avascular retina and delayed reactivation.
Journals this month
Topics moving, week to 19 Nov 2026
By field